Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Boehringer/Lilly's Linagliptin Approved: Can Renal Flexibility Unlock The DPP-4 Market?

This article was originally published in The Pink Sheet Daily

Executive Summary

Tradjenta's label supporting use in renally-impaired patients, with no need to adjust dose, could help differentiate the product's safety profile in a competitive space.
Advertisement

Related Content

Takeda Treads Carefully With DPP-4 Late-Arrival Nesina, Plans Summer Launch
FDA Seeks Clarity On DPP-4 Class Safety Signals With Linagliptin Post-Market Requirements
BI’s Tradjenta Lesson: Don’t Try To Use CV Trial To Score Head-To-Head Efficacy Evidence
CHMP Positive On Trajenta, Vectibix, Votubia And Eurartesim, But Negative On Bronchitol, Luveniq And Glybera
Questioning Authority: French Court Overturns Health Agency's Diabetes Guidelines, Citing Conflict Of Interest Rules
Boehringer/Lilly To Price Tradjenta On Par With Rival DPP-4 Inhibitors
In Deal With BI, Lilly Gets Late-Stage Diabetes Drugs
Boehringer Ingelheim Plays Catch-Up In Diabetes, Close To Filing DPP-4 Drug
Boehringer Ingelheim Plays Catch-Up In Diabetes, Close To Filing DPP-4 Drug
AstraZeneca/Bristol's Onglyza Gains Approval, But Now Has To Face Januvia

Topics

Advertisement
UsernamePublicRestriction

Register

PS072263

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel